Patent regimes
Sí, podemos impedir que las patentes obstaculicen el tratamiento de la tuberculosis

Un día antes del Día Mundial de la Tuberculosis, la Oficina de Patentes de la India rechazó la solicitud del gigante farmacéutico Jannsen de prorrogar la patente del medicamento bedaquilina.

Corporate interests are determining US response to COVID-19

Dr. Hani Serag of the People’s Health Movement talks about the huge number of COVID-19 cases that are being reported across the US.

How can countries overcome US monopoly over Remdesivir?

After making America sick again, president Donald Trump is trying to compensate for his administration’s failure by buying up the entire stock of Remdesivir from Gilead for the next three months for the US, and leaving nothing for the rest of the world.

Global north has forgotten that private sector wants ill-health

The increasing corporatisation of the health sector has meant that private interests not only play a huge role in determining policy, but also control licensing. This is a threat for countries like India.

Public health and private profits under COVID-19 pandemic

The pandemic might be devastating countries, the people and their livelihoods, but is good for some companies and their stockholders, like the ones that hold patents for N95 masks, lifesaving medicines or vaccines.

How can we confront patent regimes in the fight against COVID-19?

Newsclick’s Prabir Purkayastha talks about issues around intellectual property rights in the time of the COVID-19 pandemic.